Don't see a possible positive spin on financing, anyone?
You would think if they could have gotten a price above $6, they would have gone for it. Have to wonder what is going to be the offering price after the new publication, publicity, name change, new management, red hot biotech market failed to entice any investor or partnership.
Something is just not right here.